RNeasy Mini Kit

High-quality total RNA in minutes.

Investigator 24plex QS Kit

Multiplex amplification for human ID, with CODIS and European standard markers.

QIAsphere

Monitor and manage your QIAsphere-ready instruments from anywhere, using any mobile device.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Find out more

QIAGENbioinformatics.com

COVID-19 testing and research

Up to date protocols and list of COVID-19 testing and research solutions.

RNeasy Mini Kit

High-quality total RNA in minutes.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QuantiFERON-TB Gold Plus

Detect TB infection with confidence.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Key Figures

Home  >  Investor Relations  >  At a Glance  >  Key Figures
Years ended December 31
$1,000 except per share data 2021 2020 2019 2018 2017
Result
Net sales 2,251,657 1,870,346 1,526,424 1,501,848 1,417,536
Operating income (loss) 630,084 386,431 (26,136) 266,581 153,419
Net income (loss) 512,599 359,188 (41,455) 190,380 40,394
Basic earnings (loss) per share (EPS) 2.25 1.57 (0.18) 0.84 0.18
Diluted earnings (loss) per share (EPS) 2.21 1.53 (0.18) 0.82 0.17
Number of shares (in thousands)
Common shares used to compute basic earnings per share1 227,983 228,427 226,777 226,640 228,074
Common shares used to compute diluted earnings per share2 232,034 234,214 226,777 233,456 233,009
Cash flow
Cash flow from operations 639,001 457,806 330,843 359,496 286,779
Capital expenditures for property, plant and equipment 189,904 132,787 117,950 109,773 90,081
Free cash flow3 449,097 325,019 212,893 249,723 196,698

As of December 31

Balance sheet
Total assets 6,146,954 5,912,530 5,235,616 5,748,332 5,038,516
Cash, cash equivalents and restricted cash 880,516 597,984 629,390 1,159,079 657,714
Total long-term liabilities, including current portion 2,380,560 2,542,144 2,032,924 2,644,373 2,174,087
Total equity 3,096,550 2,797,839 2,536,591 2,634,970 2,540,996

Please visit Financial Reports for more information.

1Weighted average number of common shares used to compute basic earnings per common share

2Weighted average number of common shares used to compute diluted earnings per common share

3Free cash flow is calculated from cash provided by operations reduced by purchases of property, plant and equipment